Financials in USD. Standardized financial statements.
A compact view of how ProQR Therapeutics N.V. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $15.28M | $18.91M | $6.51M | $3.59M | $1.33M | $1.03M | $1.93M | $4.94M | -$1.53M | $2.28M |
| Revenue Growth? | -19.2% | +190.2% | +81.2% | +169.2% | +29.7% | -46.8% | -60.9% | +423.2% | -167.0% | 0.0% |
| Cost of Revenue? | $2.60M | $0 | $0 | $0 | $0 | $0 | $116.82M | $983,511 | $1.00M | $1.28M |
| Gross Profit? | $12.68M | $18.91M | $6.51M | $3.59M | $1.33M | $1.03M | -$114.89M | $3.96M | -$2.53M | $1.00M |
| Gross Margin? | +83.0% | +100.0% | +100.0% | +100.0% | +100.0% | +100.0% | -5943.6% | +80.1% | +165.5% | +43.8% |
| Operating Expenses? | $54.84M | $49.38M | $38.37M | $68.75M | $58.55M | $43.40M | $59.38M | $42.05M | $41.99M | $41.40M |
| Operating Income? | -$42.15M | -$30.47M | -$31.86M | -$65.16M | -$57.21M | -$42.37M | -$57.45M | -$36.29M | -$40.50M | -$39.57M |
| EBITDA? | -$39.56M | -$24.12M | -$24.10M | -$56.46M | -$54.95M | -$48.44M | -$174.27M | -$35.29M | $0 | -$120.55M |
| Income Before Tax | -$40.50M | -$27.96M | -$27.81M | -$64.11M | -$60.68M | -$46.49M | -$56.61M | -$37.09M | -$43.67M | -$39.10M |
| Income Tax Expense | $18,249 | -$197,000 | -$78,000 | $96,000 | $117,000 | $124,000 | $132,000 | $1,000 | $2,000 | $0 |
| Net Income? | -$40.52M | -$27.76M | -$28.12M | -$64.42M | -$60.74M | -$46.56M | -$56.75M | -$36.89M | -$43.64M | -$39.10M |
| EPS? | $-0.38 | $-0.34 | $-0.35 | $-0.91 | $-0.96 | $-0.93 | $-1.38 | $-1.08 | $-1.72 | $-1.67 |
| Diluted EPS? | $-0.38 | $-0.34 | $-0.35 | $-0.91 | $-0.96 | $-0.93 | $-1.38 | $-1.08 | $-1.72 | $-1.67 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality